Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
AstraZeneca will record sales in other countries worldwide, for which profits shared with DaiichiSankyo will be recorded within cost of sales. DaiichiSankyo will manufacture and supply ...